ABBOTT LABORATORIES
Last · NYSE$104.17+1.20 (+1.17%)live · yahoo · 2h ago
Market cap$181.44B1.74B sh
P/E · TTM33.5fwd 17.2 · eps 3.11
Beta0.58vs S&P 500
Div yield2.46%annual · TTM
52w range
$81.97$132.03
Volume415.1Ksession
| Revenue | $46.6B |
|---|---|
| Operating income | $7.3B |
| Net income | $5.4B |
| Free cash flow | $7.8B |
| Operating margin | 15.8% |
| Net margin | 11.6% |
| Return on equity | 10.6% |
| Period | TTM 2026-06-30 |
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-02-20
- Exact Sciences Acquisition
- Acquisition Leverage
- Medical Devices Growth
- Cgm Sales
- Diagnostics Decline
- Nutrition Weakness
- Infant Formula Litigation
- International Exposure
Red flags
- Abbott had $12.9 billion of debt at December 31, 2025 and plans approximately $20 billion of additional borrowings for Exact Sciences; current debt maturities include $3.0 billion in 2026 and $7.4 billion from 2031 onward.
- The pending transaction carries material financing risk: the bridge facility is capped at $20.0 billion and further borrowing could raise interest costs, weaken credit ratings, and reduce financial flexibility.
- NEC-related infant-formula litigation remains unreserved because outcomes cannot be reasonably estimated; one Missouri jury awarded $495 million, while related cases remain on appeal and could materially affect results.
- COVID-19 testing revenue fell from $1.6 billion in 2023 to $297 million in 2025, contributing to a Diagnostics margin decline from 24.4% in 2023 to 19.5% in 2025.
- Abbott states that third-party manufacturers and single suppliers are used for certain products and materials, creating potential production, recall, and availability exposure if manufacturing problems arise.
Upcoming earnings
2:30 PM UTC+2
Period
Sep 2026
Est. EPS
$1.41
Est. revenue
13.0B